Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

GBS type III oligosaccharides containing a minimal protective epitope can be turned into effective vaccines by multivalent presentation.

Carboni F, Angiolini F, Fabbrini M, Brogioni B, Corrado A, Berti F, Adamo R, Margarit I.

J Infect Dis. 2019 Oct 23. pii: jiz551. doi: 10.1093/infdis/jiz551. [Epub ahead of print]

PMID:
31641758
2.

Safety and immunogenicity of a second dose of an investigational maternal trivalent Group B streptococcus vaccine in non-pregnant women 4-6 years after a first dose: results from a phase 2 trial.

Leroux-Roels G, Bebia Z, Maes C, Aerssens A, De Boever F, Grassano L, Buffi G, Margarit I, Karsten A, Cho S, Slobod K, Corsaro B, Henry O.

Clin Infect Dis. 2019 Aug 8. pii: ciz737. doi: 10.1093/cid/ciz737. [Epub ahead of print]

PMID:
31394574
3.

Novel Multiplex Immunoassays for Quantification of IgG against Group B Streptococcus Capsular Polysaccharides in Human Sera.

Buffi G, Galletti B, Stella M, Proietti D, Balducci E, Romano MR, Mori E, Fabbrini M, Giuliani MM, Berti F, Margarit I.

mSphere. 2019 Aug 7;4(4). pii: e00273-19. doi: 10.1128/mSphere.00273-19.

4.

Factors affecting the decision to undergo abortion in Romania: Experiences at our clinic.

Ples L, Popescu I, Margarit I, Ionescu CA, Cazaceanu A, Moga MA, Popescu M, Tomescu DR, Sima RM.

J Eval Clin Pract. 2019 Jul 31. doi: 10.1111/jep.13250. [Epub ahead of print]

PMID:
31368205
5.

The Streptococcus agalactiae complement interfering protein combines multiple complement-inhibitory mechanisms by interacting with both C4 and C3 ligands.

Giussani S, Pietrocola G, Donnarumma D, Norais N, Speziale P, Fabbrini M, Margarit I.

FASEB J. 2019 Mar;33(3):4448-4457. doi: 10.1096/fj.201801991R. Epub 2018 Dec 19.

6.

European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents.

Schrag A, Martino D, Apter A, Ball J, Bartolini E, Benaroya-Milshtein N, Buttiglione M, Cardona F, Creti R, Efstratiou A, Gariup M, Georgitsi M, Hedderly T, Heyman I, Margarit I, Mir P, Moll N, Morer A, Müller N, Müller-Vahl K, Münchau A, Orefici G, Plessen KJ, Porcelli C, Paschou P, Rizzo R, Roessner V, Schwarz MJ, Steinberg T, Tagwerker Gloor F, Tarnok Z, Walitza S, Dietrich A, Hoekstra PJ; EMTICS Collaborative Group.

Eur Child Adolesc Psychiatry. 2019 Jan;28(1):91-109. doi: 10.1007/s00787-018-1190-4. Epub 2018 Jul 7.

7.

Neonatal corticosterone mitigates autoimmune neuropsychiatric disorders associated with streptococcus in mice.

Macrì S, Spinello C, Widomska J, Magliozzi R, Poelmans G, Invernizzi RW, Creti R, Roessner V, Bartolini E, Margarit I, Glennon J, Laviola G.

Sci Rep. 2018 Jul 5;8(1):10188. doi: 10.1038/s41598-018-28372-3.

8.

Fighting Antibiotic-Resistant Klebsiella pneumoniae with "Sweet" Immune Targets.

Adamo R, Margarit I.

MBio. 2018 May 15;9(3). pii: e00874-18. doi: 10.1128/mBio.00874-18.

9.

Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models.

Chiarot E, Spagnuolo A, Maccari S, Naimo E, Acquaviva A, Cecchi R, Galletti B, Fabbrini M, Mori E, Ruggiero P, Grandi G, Fontana MR, Bensi G, Margarit I.

Sci Rep. 2018 Feb 7;8(1):2593. doi: 10.1038/s41598-018-20609-5.

10.

Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women.

Fabbrini M, Rigat F, Tuscano G, Chiarot E, Donders G, Devlieger R, Filippini S, Frigimelica E, Forte P, Wittke F, Halperin SA, Slobod K, Grandi G, Margarit I.

J Infect. 2018 May;76(5):449-456. doi: 10.1016/j.jinf.2018.01.006. Epub 2018 Jan 31.

11.

Contribution of pilus type 2b to invasive disease caused by a Streptococcus agalactiae ST-17 strain.

Lazzarin M, Mu R, Fabbrini M, Ghezzo C, Rinaudo CD, Doran KS, Margarit I.

BMC Microbiol. 2017 Jul 3;17(1):148. doi: 10.1186/s12866-017-1057-8.

12.

Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide.

Carboni F, Adamo R, Fabbrini M, De Ricco R, Cattaneo V, Brogioni B, Veggi D, Pinto V, Passalacqua I, Oldrini D, Rappuoli R, Malito E, Margarit IYR, Berti F.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):5017-5022. doi: 10.1073/pnas.1701885114. Epub 2017 Apr 24.

13.

Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens.

Maruggi G, Chiarot E, Giovani C, Buccato S, Bonacci S, Frigimelica E, Margarit I, Geall A, Bensi G, Maione D.

Vaccine. 2017 Jan 5;35(2):361-368. doi: 10.1016/j.vaccine.2016.11.040. Epub 2016 Dec 7.

14.

Immune Responses to Invasive Group B Streptococcal Disease in Adults.

Edwards MS, Rench MA, Rinaudo CD, Fabbrini M, Tuscano G, Buffi G, Bartolini E, Bonacci S, Baker CJ, Margarit I.

Emerg Infect Dis. 2016 Nov;22(11):1877-1883. doi: 10.3201/eid2211.160914.

15.

Genomic Analysis Reveals Multi-Drug Resistance Clusters in Group B Streptococcus CC17 Hypervirulent Isolates Causing Neonatal Invasive Disease in Southern Mainland China.

Campisi E, Rosini R, Ji W, Guidotti S, Rojas-López M, Geng G, Deng Q, Zhong H, Wang W, Liu H, Nan C, Margarit I, Rinaudo CD.

Front Microbiol. 2016 Aug 15;7:1265. doi: 10.3389/fmicb.2016.01265. eCollection 2016.

16.

Serotype IV Streptococcus agalactiae ST-452 has arisen from large genomic recombination events between CC23 and the hypervirulent CC17 lineages.

Campisi E, Rinaudo CD, Donati C, Barucco M, Torricelli G, Edwards MS, Baker CJ, Margarit I, Rosini R.

Sci Rep. 2016 Jul 14;6:29799. doi: 10.1038/srep29799.

17.

The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera.

Fabbrini M, Rigat F, Rinaudo CD, Passalaqua I, Khacheh S, Creti R, Baldassarri L, Carboni F, Anderloni G, Rosini R, Maione D, Grandi G, Telford JL, Margarit I.

Clin Infect Dis. 2016 Sep 15;63(6):746-753. doi: 10.1093/cid/ciw377. Epub 2016 Jul 11.

PMID:
27402816
18.

Current Approaches to Group A Streptococcal Vaccine Development.

Dale JB, Batzloff MR, Cleary PP, Courtney HS, Good MF, Grandi G, Halperin S, Margarit IY, McNeil S, Pandey M, Smeesters PR, Steer AC.

In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes : Basic Biology to Clinical Manifestations [Internet]. Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2016-.
2016 Feb 10.

19.

The Group B Streptococcus-Secreted Protein CIP Interacts with C4, Preventing C3b Deposition via the Lectin and Classical Complement Pathways.

Pietrocola G, Rindi S, Rosini R, Buccato S, Speziale P, Margarit I.

J Immunol. 2016 Jan 1;196(1):385-94. doi: 10.4049/jimmunol.1501954. Epub 2015 Nov 25.

20.

Estimating the burden of invasive Group B Streptococcal disease in young infants in southern mainland China: an observational study.

Liu H, Zeng H, Wang W, Deng Q, Margarit I, Rinaudo CD, Swarthout T, Cunnington M, Ji W, Geng G.

Int J Clin Exp Med. 2015 Aug 15;8(8):13699-707. eCollection 2015.

21.

Correction to Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B Streptococcus Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide.

Nilo A, Passalacqua I, Fabbrini M, Allan M, Usera A, Carboni F, Brogioni B, Pezzicoli A, Cobb J, Romano MR, Margarit I, Hu QY, Berti F, Adamo R.

Bioconjug Chem. 2015 Oct 21;26(10):2167. doi: 10.1021/acs.bioconjchem.5b00480. Epub 2015 Sep 10. No abstract available.

PMID:
26355285
22.

Mice repeatedly exposed to Group-A β-Haemolytic Streptococcus show perseverative behaviors, impaired sensorimotor gating, and immune activation in rostral diencephalon.

Macrì S, Ceci C, Onori MP, Invernizzi RW, Bartolini E, Altabella L, Canese R, Imperi M, Orefici G, Creti R, Margarit I, Magliozzi R, Laviola G.

Sci Rep. 2015 Aug 25;5:13257. doi: 10.1038/srep13257.

23.

Group B streptococcal infections in the newborn infant and the potential value of maternal vaccination.

Berardi A, Cattelani C, Creti R, Berner R, Pietrangiolillo Z, Margarit I, Maione D, Ferrari F.

Expert Rev Anti Infect Ther. 2015;13(11):1387-99. doi: 10.1586/14787210.2015.1079126. Epub 2015 Aug 20. Review.

PMID:
26295167
24.

Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B Streptococcus Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide.

Nilo A, Passalacqua I, Fabbrini M, Allan M, Usera A, Carboni F, Brogioni B, Pezzicoli A, Cobb J, Romano MR, Margarit I, Hu QY, Berti F, Adamo R.

Bioconjug Chem. 2015 Aug 19;26(8):1839-49. doi: 10.1021/acs.bioconjchem.5b00365. Epub 2015 Jul 31. Erratum in: Bioconjug Chem. 2015 Oct 21;26(10):2167.

PMID:
26230938
25.

Noncanonical sortase-mediated assembly of pilus type 2b in group B Streptococcus.

Lazzarin M, Cozzi R, Malito E, Martinelli M, D'Onofrio M, Maione D, Margarit I, Rinaudo CD.

FASEB J. 2015 Nov;29(11):4629-40. doi: 10.1096/fj.15-272500. Epub 2015 Jul 22.

PMID:
26202865
26.

The Human Pathogen Streptococcus pyogenes Releases Lipoproteins as Lipoprotein-rich Membrane Vesicles.

Biagini M, Garibaldi M, Aprea S, Pezzicoli A, Doro F, Becherelli M, Taddei AR, Tani C, Tavarini S, Mora M, Teti G, D'Oro U, Nuti S, Soriani M, Margarit I, Rappuoli R, Grandi G, Norais N.

Mol Cell Proteomics. 2015 Aug;14(8):2138-49. doi: 10.1074/mcp.M114.045880. Epub 2015 May 27.

27.

Genomic analysis reveals the molecular basis for capsule loss in the group B Streptococcus population.

Rosini R, Campisi E, De Chiara M, Tettelin H, Rinaudo D, Toniolo C, Metruccio M, Guidotti S, Sørensen UB, Kilian M; DEVANI Consortium, Ramirez M, Janulczyk R, Donati C, Grandi G, Margarit I.

PLoS One. 2015 May 6;10(5):e0125985. doi: 10.1371/journal.pone.0125985. eCollection 2015.

28.

Structure and assembly of group B streptococcus pilus 2b backbone protein.

Cozzi R, Malito E, Lazzarin M, Nuccitelli A, Castagnetti A, Bottomley MJ, Margarit I, Maione D, Rinaudo CD.

PLoS One. 2015 May 5;10(5):e0125875. doi: 10.1371/journal.pone.0125875. eCollection 2015.

29.

Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation.

Nilo A, Morelli L, Passalacqua I, Brogioni B, Allan M, Carboni F, Pezzicoli A, Zerbini F, Maione D, Fabbrini M, Romano MR, Hu QY, Margarit I, Berti F, Adamo R.

ACS Chem Biol. 2015 Jul 17;10(7):1737-46. doi: 10.1021/acschembio.5b00247. Epub 2015 May 6.

PMID:
25906283
30.

Biofilm formation by Streptococcus agalactiae: influence of environmental conditions and implicated virulence factors.

Rosini R, Margarit I.

Front Cell Infect Microbiol. 2015 Feb 4;5:6. doi: 10.3389/fcimb.2015.00006. eCollection 2015. Review.

31.

Corrigendum: Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline.

Da Cunha V, Davies MR, Douarre PE, Rosinski-Chupin I, Margarit I, Spinali S, Perkins T, Lechat P, Dmytruk N, Sauvage E, Ma L, Romi B, Tichit M, Lopez-Sanchez MJ, Descorps-Declere S, Souche E, Buchrieser C, Trieu-Cuot P, Moszer I, Clermont D, Maione D, Bouchier C, McMillan DJ, Parkhill J, Telford JL, Dougan G, Walker MJ, Holden MT, Poyart C, Glaser P.

Nat Commun. 2015 Jan 28;6:6108. doi: 10.1038/ncomms7108. No abstract available.

32.

Tyrosine-directed conjugation of large glycans to proteins via copper-free click chemistry.

Nilo A, Allan M, Brogioni B, Proietti D, Cattaneo V, Crotti S, Sokup S, Zhai H, Margarit I, Berti F, Hu QY, Adamo R.

Bioconjug Chem. 2014 Dec 17;25(12):2105-11. doi: 10.1021/bc500438h. Epub 2014 Nov 21.

PMID:
25415860
33.

Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen.

Fantappiè L, de Santis M, Chiarot E, Carboni F, Bensi G, Jousson O, Margarit I, Grandi G.

J Extracell Vesicles. 2014 Aug 11;3. doi: 10.3402/jev.v3.24015. eCollection 2014.

34.

Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline.

Da Cunha V, Davies MR, Douarre PE, Rosinski-Chupin I, Margarit I, Spinali S, Perkins T, Lechat P, Dmytruk N, Sauvage E, Ma L, Romi B, Tichit M, Lopez-Sanchez MJ, Descorps-Declere S, Souche E, Buchrieser C, Trieu-Cuot P, Moszer I, Clermont D, Maione D, Bouchier C, McMillan DJ, Parkhill J, Telford JL, Dougan G, Walker MJ; DEVANI Consortium, Holden MTG, Poyart C, Glaser P.

Nat Commun. 2014 Aug 4;5:4544. doi: 10.1038/ncomms5544. Erratum in: Nat Commun. 2015;6:6108.

35.

Structure of the type IX group B Streptococcus capsular polysaccharide and its evolutionary relationship with types V and VII.

Berti F, Campisi E, Toniolo C, Morelli L, Crotti S, Rosini R, Romano MR, Pinto V, Brogioni B, Torricelli G, Janulczyk R, Grandi G, Margarit I.

J Biol Chem. 2014 Aug 22;289(34):23437-48. doi: 10.1074/jbc.M114.567974. Epub 2014 Jul 2.

36.

Analysis of two-component systems in group B Streptococcus shows that RgfAC and the novel FspSR modulate virulence and bacterial fitness.

Faralla C, Metruccio MM, De Chiara M, Mu R, Patras KA, Muzzi A, Grandi G, Margarit I, Doran KS, Janulczyk R.

MBio. 2014 May 20;5(3):e00870-14. doi: 10.1128/mBio.00870-14.

37.

SpyAD, a moonlighting protein of group A Streptococcus contributing to bacterial division and host cell adhesion.

Gallotta M, Gancitano G, Pietrocola G, Mora M, Pezzicoli A, Tuscano G, Chiarot E, Nardi-Dei V, Taddei AR, Rindi S, Speziale P, Soriani M, Grandi G, Margarit I, Bensi G.

Infect Immun. 2014 Jul;82(7):2890-901. doi: 10.1128/IAI.00064-14. Epub 2014 Apr 28.

38.

Acidic pH strongly enhances in vitro biofilm formation by a subset of hypervirulent ST-17 Streptococcus agalactiae strains.

D'Urzo N, Martinelli M, Pezzicoli A, De Cesare V, Pinto V, Margarit I, Telford JL, Maione D; Members of the DEVANI Study Group.

Appl Environ Microbiol. 2014 Apr;80(7):2176-85. doi: 10.1128/AEM.03627-13. Epub 2014 Jan 31.

39.

Preventing newborn infection with maternal immunization.

Black S, Margarit I, Rappuoli R.

Sci Transl Med. 2013 Jul 24;5(195):195ps11. doi: 10.1126/scitranslmed.3005451.

PMID:
23884465
40.

Targeted amino acid substitutions impair streptolysin O toxicity and group A Streptococcus virulence.

Chiarot E, Faralla C, Chiappini N, Tuscano G, Falugi F, Gambellini G, Taddei A, Capo S, Cartocci E, Veggi D, Corrado A, Mangiavacchi S, Tavarini S, Scarselli M, Janulczyk R, Grandi G, Margarit I, Bensi G.

MBio. 2013 Jan 8;4(1):e00387-12. doi: 10.1128/mBio.00387-12.

41.

Streptococcus pyogenes SpyCEP influences host-pathogen interactions during infection in a murine air pouch model.

Chiappini N, Seubert A, Telford JL, Grandi G, Serruto D, Margarit I, Janulczyk R.

PLoS One. 2012;7(7):e40411. doi: 10.1371/journal.pone.0040411. Epub 2012 Jul 27.

42.

Conserved anchorless surface proteins as group A streptococcal vaccine candidates.

Henningham A, Chiarot E, Gillen CM, Cole JN, Rohde M, Fulde M, Ramachandran V, Cork AJ, Hartas J, Magor G, Djordjevic SP, Cordwell SJ, Kobe B, Sriprakash KS, Nizet V, Chhatwal GS, Margarit IY, Batzloff MR, Walker MJ.

J Mol Med (Berl). 2012 Oct;90(10):1197-207. doi: 10.1007/s00109-012-0897-9. Epub 2012 Apr 14.

PMID:
22527883
43.

The ancillary protein 1 of Streptococcus pyogenes FCT-1 pili mediates cell adhesion and biofilm formation through heterophilic as well as homophilic interactions.

Becherelli M, Manetti AG, Buccato S, Viciani E, Ciucchi L, Mollica G, Grandi G, Margarit I.

Mol Microbiol. 2012 Mar;83(5):1035-47. doi: 10.1111/j.1365-2958.2012.07987.x. Epub 2012 Feb 10.

44.

A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus.

Fabbrini M, Sammicheli C, Margarit I, Maione D, Grandi G, Giuliani MM, Mori E, Nuti S.

J Immunol Methods. 2012 Apr 30;378(1-2):11-9. doi: 10.1016/j.jim.2012.01.011. Epub 2012 Jan 30.

45.

Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case.

Bensi G, Mora M, Tuscano G, Biagini M, Chiarot E, Bombaci M, Capo S, Falugi F, Manetti AG, Donato P, Swennen E, Gallotta M, Garibaldi M, Pinto V, Chiappini N, Musser JM, Janulczyk R, Mariani M, Scarselli M, Telford JL, Grifantini R, Norais N, Margarit I, Grandi G.

Mol Cell Proteomics. 2012 Jun;11(6):M111.015693. doi: 10.1074/mcp.M111.015693. Epub 2012 Jan 27.

46.

Genomic organization, structure, regulation and pathogenic role of pilus constituents in major pathogenic Streptococci and Enterococci.

Kreikemeyer B, Gámez G, Margarit I, Giard JC, Hammerschmidt S, Hartke A, Podbielski A.

Int J Med Microbiol. 2011 Mar;301(3):240-51. doi: 10.1016/j.ijmm.2010.09.003. Epub 2010 Nov 26. Review.

PMID:
21112248
47.

Environmental acidification drives S. pyogenes pilus expression and microcolony formation on epithelial cells in a FCT-dependent manner.

Manetti AG, Köller T, Becherelli M, Buccato S, Kreikemeyer B, Podbielski A, Grandi G, Margarit I.

PLoS One. 2010 Nov 5;5(11):e13864. doi: 10.1371/journal.pone.0013864.

48.

Evaluation of a Group A Streptococcus synthetic oligosaccharide as vaccine candidate.

Kabanova A, Margarit I, Berti F, Romano MR, Grandi G, Bensi G, Chiarot E, Proietti D, Swennen E, Cappelletti E, Fontani P, Casini D, Adamo R, Pinto V, Skibinski D, Capo S, Buffi G, Gallotta M, Christ WJ, Campbell AS, Pena J, Seeberger PH, Rappuoli R, Costantino P.

Vaccine. 2010 Dec 10;29(1):104-14. doi: 10.1016/j.vaccine.2010.09.018. Epub 2010 Sep 24.

PMID:
20870056
49.

Emergence and global dissemination of host-specific Streptococcus agalactiae clones.

Sørensen UB, Poulsen K, Ghezzo C, Margarit I, Kilian M.

MBio. 2010 Aug 24;1(3). pii: e00178-10. doi: 10.1128/mBio.00178-10.

50.

Streptococcus pyogenes SpyCEP: a chemokine-inactivating protease with unique structural and biochemical features.

Zingaretti C, Falugi F, Nardi-Dei V, Pietrocola G, Mariani M, Liberatori S, Gallotta M, Tontini M, Tani C, Speziale P, Grandi G, Margarit I.

FASEB J. 2010 Aug;24(8):2839-48. doi: 10.1096/fj.09-145631. Epub 2010 Mar 25.

PMID:
20339024

Supplemental Content

Loading ...
Support Center